Overall, our findings suggest that high EGR3 protein expression was associated with a poor prognosis in GBM patients with a methylated MGMT-promoter, while EGR1 expression was not associated with prognosis after adjustment for clinically relevant confounders. Here, EGR3 is linked to glioblastoma.